Overexpression of RhoV Promotes the Progression and EGFR-TKI Resistance of Lung Adenocarcinoma
Hongjin Chen(Guangzhou University of Chinese Medicine), Yongsheng Wang(Guangzhou University of Chinese Medicine)
Cited by 31
Related Papers
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|504
Dopamine receptor antagonist thioridazine inhibits tumor growth in a murine breast cancer model
|Molecular Medicine Reports|2015|53
Continuous exposure of non-small cell lung cancer cells with wild-type EGFR to an inhibitor of EGFR tyrosine kinase induces chemoresistance by activating STAT3
|International Journal of Oncology|2015|27